Coronavirus Clinical Trial
Official title:
A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia
In December 2019, a novel coronavirus infectious disease characterized by acute respiratory impairment due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan city of Hubei province in China. So far no specific antiviral therapy can be available for patients with SARS-CoV-2 infection. Although symptomatic and supportive care, even with mechanical ventilation or extracorporeal membrane oxygenation (ECMO), are strongly recommended for severe infected individuals, those with advancing age and co-morbidities such as diabetes and heart disease remain to be at high risk for adverse outcomes. This pilot clinical trial will be performed to explore the safety and efficiency of aerosol inhalation of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo) in severe patients with novel coronavirus pneumonia (NCP).
Since December 2019, SARS-CoV-2 infection has become a worldwide urgent public health event,
especially in China. As of February 13, 2020, over 63,000 cases have been confirmed with over
10,200 severe cases in mainland of China. There is currently no vaccine or specific antiviral
treatment existing for SARS-CoV-2 infection. Although symptomatic and supportive care are
recommended for severe infected individuals, those with advancing age and co-morbidities such
as diabetes and heart disease remain to be at high risk for adverse outcomes, with mortality
of ~10%. Therefore, it is urgent to find a safe and effective therapeutic approach to
patients with severe coronavirus disease-19(COVID-19) characterized by an severe acute
respiratory impairment.
Experimental studies have demonstrated that mesenchymal stem cells (MSCs) or their exosomes
(MSCs-Exo) significantly reduced lung inflammation and pathological impairment resulting from
different types of lung injury. In addition, macrophage phagocytosis, bacterial killing and
outcome are improved. It is highly likely that MSCs-Exo have the same therapeutic effect on
inoculation pneumonia as MSCs themselves.
Although human bone marrow MSCs have been safely administered in patients with ARDS and
septic shock (phase I/II trials), it seems safer to deliver MSCs-Exo rather than live MSCs.
The intravenous administration of MSCs may result in aggregating or clumping in the injured
microcirculation and carries the risk of mutagenicity and oncogenicity, which do not exist by
treating with nebulized MSCs-Exo. Another advantage of MSCs-Exo over MSCs is the possibility
of storing them for several weeks/months allowing their safe transportation and delayed
therapeutic use.
The purpose of this single-arm design, open label, combined interventional clinical trial,
therefore, is to explore the safety and efficiency of aerosol inhalation of the exosomes
derived from allogenic adipose mesenchymal stem cells (MSCs-Exo) in the treatment of severe
patients hospitalized with novel coronavirus pneumonia (NCP).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Completed |
NCT04556149 -
imPulseā¢ Una Full-spectrum, Over Clothing E-stethoscope
|